Features prior to DLI and ICD
Features . | ICD* . | P2-155 . | ||||
---|---|---|---|---|---|---|
Total n = 344 . | Group A† n = 98 . | Group B‡ n = 107 . | Group C2-153 n = 93 . | Not available n = 46 . | ||
% . | % . | % . | % . | % . | ||
Patient age | ||||||
Younger than 40 y | 54 | 61 | 45 | 53 | 61 | .22 |
40 y and older | 46 | 39 | 55 | 47 | 39 | |
Donor type | ||||||
SIB | 79 | 70 | 79 | 90 | 72 | <.01 |
VUD | 21 | 30 | 21 | 10 | 28 | |
Sex of donor | ||||||
Male | 67 | 73 | 56 | 69 | 72 | .53 |
Female | 33 | 27 | 44 | 31 | 28 | |
Sex match with the donor | ||||||
Matched | 55 | 62 | 41 | 59 | 65 | .71 |
Mismatched | 45 | 38 | 59 | 41 | 35 | |
Phase at SCT | ||||||
First chronic phase | 79 | 84 | 79 | 77 | 74 | .28 |
More advanced | 21 | 16 | 21 | 23 | 26 | |
T-cell depletion at SCT | ||||||
No | 58 | 38 | 53 | 75 | 82 | <.01 |
Yes | 42 | 62 | 47 | 25 | 18 | |
Interval SCT-first infusion | ||||||
Fewer than 2 y | 44 | 46 | 47 | 39 | 45 | .32 |
More than 2 y | 56 | 54 | 53 | 61 | 55 | |
Acute GVHD after SCT | ||||||
Grade 0 | 44 | 33 | 46 | 51 | 53 | .03 |
Grade I | 30 | 36 | 27 | 29 | 22 | |
Grades II-IV | 26 | 32 | 27 | 20 | 25 | |
Chronic GVHD after SCT | ||||||
None | 69 | 64 | 70 | 73 | 67 | .31 |
Limited | 22 | 28 | 20 | 19 | 23 | |
Extensive | 9 | 8 | 10 | 7 | 9 | |
GVHD after SCT | ||||||
None | 38 | 25 | 40 | 42 | 51 | .04 |
Grade I and/or limited | 32 | 38 | 31 | 33 | 20 | |
Grade higher than I and/or extensive | 30 | 37 | 29 | 25 | 29 | |
Stage of relapse at DLI | ||||||
Molecular/cytogenetic | 30 | 42 | 32 | 19 | 24 | <.01 |
Hematologic | 52 | 49 | 47 | 60 | 52 | |
Transformed | 18 | 9 | 21 | 21 | 24 | |
Date of DLI | ||||||
1988-1995 | 53 | 26 | 55 | 80 | 57 | <.01 |
1996-1998 | 47 | 74 | 45 | 20 | 43 |
Features . | ICD* . | P2-155 . | ||||
---|---|---|---|---|---|---|
Total n = 344 . | Group A† n = 98 . | Group B‡ n = 107 . | Group C2-153 n = 93 . | Not available n = 46 . | ||
% . | % . | % . | % . | % . | ||
Patient age | ||||||
Younger than 40 y | 54 | 61 | 45 | 53 | 61 | .22 |
40 y and older | 46 | 39 | 55 | 47 | 39 | |
Donor type | ||||||
SIB | 79 | 70 | 79 | 90 | 72 | <.01 |
VUD | 21 | 30 | 21 | 10 | 28 | |
Sex of donor | ||||||
Male | 67 | 73 | 56 | 69 | 72 | .53 |
Female | 33 | 27 | 44 | 31 | 28 | |
Sex match with the donor | ||||||
Matched | 55 | 62 | 41 | 59 | 65 | .71 |
Mismatched | 45 | 38 | 59 | 41 | 35 | |
Phase at SCT | ||||||
First chronic phase | 79 | 84 | 79 | 77 | 74 | .28 |
More advanced | 21 | 16 | 21 | 23 | 26 | |
T-cell depletion at SCT | ||||||
No | 58 | 38 | 53 | 75 | 82 | <.01 |
Yes | 42 | 62 | 47 | 25 | 18 | |
Interval SCT-first infusion | ||||||
Fewer than 2 y | 44 | 46 | 47 | 39 | 45 | .32 |
More than 2 y | 56 | 54 | 53 | 61 | 55 | |
Acute GVHD after SCT | ||||||
Grade 0 | 44 | 33 | 46 | 51 | 53 | .03 |
Grade I | 30 | 36 | 27 | 29 | 22 | |
Grades II-IV | 26 | 32 | 27 | 20 | 25 | |
Chronic GVHD after SCT | ||||||
None | 69 | 64 | 70 | 73 | 67 | .31 |
Limited | 22 | 28 | 20 | 19 | 23 | |
Extensive | 9 | 8 | 10 | 7 | 9 | |
GVHD after SCT | ||||||
None | 38 | 25 | 40 | 42 | 51 | .04 |
Grade I and/or limited | 32 | 38 | 31 | 33 | 20 | |
Grade higher than I and/or extensive | 30 | 37 | 29 | 25 | 29 | |
Stage of relapse at DLI | ||||||
Molecular/cytogenetic | 30 | 42 | 32 | 19 | 24 | <.01 |
Hematologic | 52 | 49 | 47 | 60 | 52 | |
Transformed | 18 | 9 | 21 | 21 | 24 | |
Date of DLI | ||||||
1988-1995 | 53 | 26 | 55 | 80 | 57 | <.01 |
1996-1998 | 47 | 74 | 45 | 20 | 43 |